Adagio Medical Holdings, Inc (ADGM)

Adagio Medical Holdings, Inc.'s stock price has experienced a decline of approximately 39.60% over the past six months. In October 2025, Adagio Medical announced a private placement of securities. In November 2025, the company reported a net loss for the third quarter. In December 2025, CEO Todd Usen purchased shares of the company's common stock. In March 2026, Adagio Medical reported its fourth-quarter and full-year 2025 financial results, with a reduced net loss. Also in March 2026, the company announced the completion of enrollment in its FULCRUM-VT pivotal IDE trial and the publication of pre-clinical results for a next-generation ventricular ablation catheter. Adagio Medical also highlighted recent successful expanded access cases with its vCLAS™ System in March 2026.

Information regarding specific demand seasonality for Adagio Medical Holdings, Inc.'s products and services was not found in the provided search results. Given the nature of its medical devices for cardiac arrhythmias, demand may be relatively stable rather than subject to significant seasonal fluctuations.

Adagio Medical Holdings, Inc. is a medical device company in the Healthcare sector, focusing on cardiovascular and electrophysiology. The company's core business revolves around its Ultra-Low Temperature Cryoablation (ULTC) technology platform, designed to create large, durable lesions in cardiac tissue to treat arrhythmias. Its major products include the vCLAS™ Cryoablation System, the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories, and the Cryopulse atrial pulsed-field cryoablation catheter and accessories. The vCLAS™ Cryoablation System is specifically designed for treating ventricular tachycardia (VT) and monomorphic ventricular tachycardia (MMVT).

Adagio Medical Holdings, Inc. has a presence in Europe and other select geographies where its vCLAS™ Cryoablation System is CE Marked and commercially available for the treatment of monomorphic ventricular tachycardia. In the United States, the vCLAS™ system is currently limited to investigational use and is being evaluated in the FULCRUM‑VT U.S. IDE pivotal study. The company's strategic focus for market expansion includes North American and European companies in the life sciences and medical technology sectors.

Adagio Medical Holdings, Inc. has maintained a positive brand reputation over the past year, marked by significant clinical and regulatory achievements. The company received FDA Breakthrough Device Designation for its vCLAS™ Cryoablation System in April 2025. The company has announced the publication of positive pre-clinical results for its next-generation ventricular ablation catheter and highlighted successful expanded access cases with its vCLAS™ System. The completion of enrollment in the FULCRUM-VT pivotal IDE trial is another positive development.

Adagio Medical Holdings, Inc. has a significant level of institutional ownership, with 48.08% of its stock held by institutional investors. As of March 20, 2026, there were 23 institutional owners and shareholders holding a total of 16,645,650 shares. Major institutional owners include Perceptive Advisors Llc, Sio Capital Management, LLC, Adage Capital Partners Gp, L.l.c., Alyeska Investment Group, L.P., ADAR1 Capital Management, LLC, Silverarc Capital Management, Llc, Armistice Capital, Llc, Hudson Bay Capital Management LP, Shaolin Capital Management LLC, and Opaleye Management Inc. Perceptive Advisors LLC is noted as a particularly large shareholder.